Holen Sie sich die Stockscreener-App
28.10
7.46%
1.95
Handel nachbörslich:
28.22
0.12
+0.43%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$26.15
Offen:
$26.98
24-Stunden-Volumen:
9.88M
Relative Volume:
1.45
Marktkapitalisierung:
$14.51B
Einnahmen:
$11.32B
Nettoeinkommen (Verlust:
$-981.00M
KGV:
-14.39
EPS:
-1.9532
Netto-Cashflow:
$714.00M
1W Leistung:
+20.39%
1M Leistung:
+24.06%
6M Leistung:
+41.14%
1J Leistung:
+27.96%
1-Tages-Spanne:
$26.90
$28.30
1-Wochen-Bereich:
$23.57
$30.00
52-Wochen-Spanne:
$15.73
$30.00
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(224) 948-2000
Adresse
ONE BAXTER PARKWAY, DEERFIELD, IL
Compare BAX vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
28.10 | 12.05B | 11.32B | -981.00M | 714.00M | -1.9532 |
ISRG
Intuitive Surgical Inc
|
375.41 | 127.84B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
170.21 | 43.79B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
70.21 | 32.81B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
40.47 | 33.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
215.19 | 29.46B | 5.54B | 1.52B | 1.74B | 10.37 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-31 | Herabstufung | Argus | Buy → Hold |
| 2025-08-04 | Herabstufung | Stifel | Buy → Hold |
| 2025-08-01 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
Stifel raises Baxter stock price target on segment restructuring - Investing.com
Baxter issues recall of antibiotic IV bags after bits of cardboard flagged in solution - Fierce Pharma
UBS Adjusts Price Target on Baxter International to $25 From $19, Maintains Neutral Rating - marketscreener.com
Stifel Adjusts Price Target on Baxter International to $24 From $19, Maintains Hold Rating - marketscreener.com
Analysts Offer Insights on Healthcare Companies: InflaRx (IFRX) and Baxter International (BAX) - The Globe and Mail
Why Baxter (BAX) Stock Is Up Today - Yahoo Finance
BAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG / ML) SINGLE-DOSE INFUSION BAG IN 100ML DUE TO PARTICULATE MATTER FOUND IN SOLUTION - Solomon's Words for the Wise
Baxter International Inc (BAX) Shares Surge 4.2% -- What GF Scor - GuruFocus
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Baxter International Inc (BAX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Baxter International Q2 2026 Earnings Preview — July 30, Street Expects $0.37 EPS - AlphaStreet
TD Cowen Adjusts Price Target on Baxter International to $24 From $20, Maintains Hold Rating - Moomoo
BAX|Baxter International Inc|Price:23.335|Chg%:+0.935 - TradingKey
Baxter International Inc (BAX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Baxter International Inc (BAX) Cash Flow - TradingKey
Baxter International Inc (BAX) Income Statement - TradingKey
Baxter International Inc (BAX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Baxter International Inc (BAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Baxter International Inc (BAX) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Bank of New York Mellon Corp Reduces Holdings in Baxter International Inc. $BAX - MarketBeat
A Look at Baxter International Inc (BAX) After 3.4% Gain -- GF V - GuruFocus
Will Baxter's Q2 Results Continue to Reflect Operational Headwinds? - Yahoo Finance
Baxter stock trades steadily as spin-off and transformation reshape earnings profile - AD HOC NEWS
Earnings Preview: Baxter International (BAX) Q2 Earnings Expected to Decline - Yahoo Finance
Baxter International (BAX) Projected to Release Earnings on Thursday - MarketBeat
Baxter International stock trades steadily as spin-off plans follow mixed 2023 results - Ad-hoc-news.de
Baxter International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
How Investors May Respond To Baxter (BAX) Class I VOLARA Recall And Quality Control Scrutiny - Sahm
Baxter stock trades steady as spin-off and portfolio reshaping shift focus toward margins - Ad-hoc-news.de
Baxter International stock trades steadily as core therapies support earnings and spin-off integrati - Ad-hoc-news.de
Baxter International Inc. stock underperforms Monday when compared to competitors - MarketWatch
Baxter stock remains supported by its latest reported results - Ad-hoc-news.de
Baxter International stock trades steadily as spin-off and cost actions reshape earnings profile - Ad-hoc-news.de
Baxter International stock trades steady as spin-off of kidney care business and margin focus shape - Ad-hoc-news.de
Baxter: The Chart Points Higher, Valuation And Growth Are Less Appealing - Seeking Alpha
Baxter International Appoints Michael Lemberger as Director of People Analytics - hrtoday.in
Baxter International stock trades steadily as spin-off and portfolio reshaping reshape earnings prof - Ad-hoc-news.de
Baxter International (BAX) Q4 2024 earnings summary - Quartr
Is Baxter International Inc (BAX) a Bargain After 3.2% Drop? GF Value Says Undervalued - GuruFocus
Baxter International Inc. stock underperforms Friday when compared to competitors - MarketWatch
Baxter stock trades steady as spin-off and earnings reshape the profile - Ad-hoc-news.de
Sumitomo Mitsui Trust Group Inc. Cuts Holdings in Baxter International Inc. $BAX - MarketBeat
Baxter International Inc. (NYSE:BAX) Given Average Rating of "Reduce" by Analysts - MarketBeat
Baxter International Inc. Stock Climbs 5.4%, Outperforms Peers - webull.com
Baxter International's Q2 2026 earnings: What to expect - MSN
Baxter stock holds steady as restructuring and spin-off reshape the portfolio - Ad-hoc-news.de
Is Baxter’s Class I Respiratory Device Recall Reshaping the Investment Case for Baxter International (BAX)? - Sahm
Baxter International Updates Segment Reporting Structure and Metrics - The Globe and Mail
How Baxter International Inc. (BAX) Affects Rotational Strategy Timing - Stock Traders Daily
Q2 EPS Forecast for Baxter International Lowered by Analyst - MarketBeat
Baxter International (BAX) Announces Recast of Financial Reporti - GuruFocus
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):